CN111234022A - 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用 - Google Patents
抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用 Download PDFInfo
- Publication number
- CN111234022A CN111234022A CN201911295509.2A CN201911295509A CN111234022A CN 111234022 A CN111234022 A CN 111234022A CN 201911295509 A CN201911295509 A CN 201911295509A CN 111234022 A CN111234022 A CN 111234022A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- hybridoma cell
- acetylglucosamine transferase
- protein
- cell strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 42
- 229950006780 n-acetylglucosamine Drugs 0.000 title claims abstract description 34
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 title claims abstract description 32
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 title claims abstract description 32
- 102000004357 Transferases Human genes 0.000 title claims abstract description 26
- 108090000992 Transferases Proteins 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 102000035118 modified proteins Human genes 0.000 title claims abstract description 16
- 108091005573 modified proteins Proteins 0.000 title claims abstract description 16
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 239000012634 fragment Substances 0.000 claims description 21
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 14
- 241000699670 Mus sp. Species 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 230000003321 amplification Effects 0.000 claims description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 8
- 238000010367 cloning Methods 0.000 claims description 8
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 210000004989 spleen cell Anatomy 0.000 claims description 6
- 238000001976 enzyme digestion Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000003259 recombinant expression Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 241000672609 Escherichia coli BL21 Species 0.000 claims description 3
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 239000007928 intraperitoneal injection Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 6
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 102100031929 UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit Human genes 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 21
- 101710117112 UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit Proteins 0.000 description 19
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 239000002609 medium Substances 0.000 description 11
- 238000011084 recovery Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000992235 Homo sapiens UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase 110 kDa subunit Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 238000009210 therapy by ultrasound Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 101100242063 Caenorhabditis elegans ogt-1 gene Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 2
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical group OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- -1 N-acetylglucosaminyl Chemical group 0.000 description 1
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
- 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 230000006271 O-GlcNAcylation Effects 0.000 description 1
- 101150044251 OGT gene Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 125000000311 mannosyl group Chemical class C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
OGT1:OGT2:OGT3(质量比) | 免疫小鼠抗体滴度 | 评价 |
1:1:1 | 1:25600 | |
1:2:1 | 1:204800 | 最优 |
1:2:2 | 1:102400 | |
2:1:1 | 1:51200 | |
2:1:2 | 1:25600 | |
2:2:1 | 1:51200 | |
1:1:2 | 1:102400 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911295509.2A CN111234022B (zh) | 2019-12-16 | 2019-12-16 | 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911295509.2A CN111234022B (zh) | 2019-12-16 | 2019-12-16 | 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111234022A true CN111234022A (zh) | 2020-06-05 |
CN111234022B CN111234022B (zh) | 2024-03-22 |
Family
ID=70873902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911295509.2A Active CN111234022B (zh) | 2019-12-16 | 2019-12-16 | 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111234022B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014028939A2 (en) * | 2012-08-17 | 2014-02-20 | California Institute Of Technology | Targeting phosphofructokinase and its glycosylation form for cancer |
WO2014159244A2 (en) * | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | O-GlcNAc TAU ANTIBODY AND USE THEREOF |
CN105408480A (zh) * | 2013-03-11 | 2016-03-16 | 北卡罗来纳大学教堂山分校 | 用于靶向o-连接的n-乙酰氨基葡萄糖转移酶和促进伤口愈合的组合物和方法 |
CN109071668A (zh) * | 2016-02-19 | 2018-12-21 | 杭州惠瑞生物医药有限公司 | 抗n-乙酰基葡萄糖胺和n-乙酰基-半乳糖胺的抗体 |
CN109870577A (zh) * | 2017-12-05 | 2019-06-11 | 复旦大学 | O-连接的n-乙酰氨基葡萄糖合成酶ogt在制备肝癌预后分子标志物中的应用 |
-
2019
- 2019-12-16 CN CN201911295509.2A patent/CN111234022B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014028939A2 (en) * | 2012-08-17 | 2014-02-20 | California Institute Of Technology | Targeting phosphofructokinase and its glycosylation form for cancer |
CN105408480A (zh) * | 2013-03-11 | 2016-03-16 | 北卡罗来纳大学教堂山分校 | 用于靶向o-连接的n-乙酰氨基葡萄糖转移酶和促进伤口愈合的组合物和方法 |
WO2014159244A2 (en) * | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | O-GlcNAc TAU ANTIBODY AND USE THEREOF |
CN109071668A (zh) * | 2016-02-19 | 2018-12-21 | 杭州惠瑞生物医药有限公司 | 抗n-乙酰基葡萄糖胺和n-乙酰基-半乳糖胺的抗体 |
CN109870577A (zh) * | 2017-12-05 | 2019-06-11 | 复旦大学 | O-连接的n-乙酰氨基葡萄糖合成酶ogt在制备肝癌预后分子标志物中的应用 |
Non-Patent Citations (3)
Title |
---|
张迪;张瑜;陈丹阳;陈博雅;修玉宗;于文功;顾玉超;: "OGT多克隆抗体的制备及特异性分析", 现代生物医学进展, no. 03, pages 24 - 28 * |
陈媛 等: "《药理作用和临床应用》", 30 May 2019, 吉林科学技术出版社, pages: 189 * |
韩宝仙;高晓冬;中西秀树;: "人体线粒体N-乙酰氨基葡萄糖转移酶在酿酒酵母中的表达", 食品与生物技术学报, no. 09, pages 987 - 992 * |
Also Published As
Publication number | Publication date |
---|---|
CN111234022B (zh) | 2024-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112111462B (zh) | 烯醇化酶eno1单克隆抗体及其应用 | |
EP2121920A2 (en) | Method for cloning cognate antibodies | |
CN113699118B (zh) | 一种杂交瘤细胞株及其产生的抗体和应用 | |
US20100069262A1 (en) | Method for Cloning Avian-Derived Antibodies | |
US20210002699A1 (en) | Tim-3 nanobody, a preparation method thereof, and use thereof | |
CN110218250A (zh) | 一种草鱼补体成分5多克隆抗体的制备方法 | |
CN109777785B (zh) | 杂交瘤细胞株及其应用 | |
CN109971726B (zh) | 杂交瘤细胞株及其产生的抗体和制备方法 | |
CN117230020B (zh) | 一种g10 epsps单抗杂交瘤细胞株及其产生的抗体和应用 | |
CN111234022B (zh) | 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用 | |
CN114560945B (zh) | 特异性结合红霉素的新型单克隆抗体及其应用 | |
CN103173457A (zh) | 抗cd20单克隆抗体可变区序列及其制备方法 | |
CN110205300B (zh) | Bar单抗杂交瘤细胞株、产生的抗体及其制备方法 | |
CN112342198A (zh) | PAT/pat单抗杂交瘤细胞株、产生的抗体及其制备方法 | |
CN108486066B (zh) | 一种杂交瘤细胞株及其分泌的抗流产衣原体的单抗 | |
CN111454365A (zh) | 抗msh6蛋白单克隆抗体、细胞系及其制备方法和应用 | |
CN112111496A (zh) | 稀有鮈鲫载脂蛋白ApoE基因、重组蛋白、多克隆抗体及制备方法和应用 | |
CN109593132B (zh) | 用于治疗癌症的单克隆抗体及其应用 | |
CN114773456B (zh) | 抗pk34单克隆抗体和杂交瘤细胞系及其制备和纯化方法 | |
CN115094042A (zh) | PAT/pat单抗杂交瘤细胞株及其产生的抗体和应用 | |
CN113637079B (zh) | 抗setd3的单克隆抗体及其用途 | |
Kaur et al. | Preparation of monoclonal antibodies against human telomerase | |
CN117230021B (zh) | 一种cp4 epsps单抗杂交瘤细胞株及其产生的抗体和应用 | |
CN114891101B (zh) | 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用 | |
AU2021104248A4 (en) | Recombinant Human VASN Protein-LRR Domain Protein and Monoclonal Antibody Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240229 Address after: 210009 No. 26, Ma Jia street, Jiangsu, Nanjing Applicant after: Jiangsu Provincial Institute of Materia Medica Co.,Ltd. Country or region after: China Address before: 210000 Jiangbei New District, Nanjing, Jiangsu Province, Room 1319, Unit 2, 02 Building, No. 8 Wanhui City (North District), Pukou Avenue, Jiangbei New District, Jiangsu Province Applicant before: Nanjing Tester Biotechnology Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |